Key Highlights

  • Zoono received further shelf-life extension orders of circa NZ$700,000 in July 2026, with unaudited July sales of NZ$625,000 and an unaudited profit of NZ$110,000.
  • Its UK customer has offered accelerated payment terms, and further orders are expected in September.
  • The update covers one month of unaudited figures and does not provide a full-year outlook or guidance.

Zoono Group Limited (ASX:ZNO), a New Zealand-headquartered antimicrobial technology company, issued a company update on 4 August 2026 on its trading at the start of FY27. The announcement follows the Quarterly Report (Appendix 4C) the company lodged on 7 July 2026 and covers orders and sales for July, online sales and activity in India. All figures in it are unaudited.

Shelf-life extension orders

In line with expectations set out in the 7 July quarterly report, Zoono received further shelf-life extension orders of circa NZ$700,000 in July. The company reports unaudited July sales of NZ$625,000 and an unaudited profit of NZ$110,000 for the month. The release does not say how many customers placed the orders, what the orders cover in unit terms, or when they will be delivered and recognised as sales, so the relationship between the NZ$700,000 of orders and the NZ$625,000 of sales is not explained.

Customer payment terms

The company says accelerated payment terms have been offered by its UK customer. The announcement does not state the terms, the size of the receivable involved or whether the offer has been accepted into a formal arrangement. Zoono also says it expects further orders in September 2026, which is described as an expectation and not a contracted position.

Online sales

Online sales for July increased, which Zoono attributes to the re-introduction for sale of its mould and foot guard products and its body and surface wipes. No online sales figure, growth rate or comparison period is given, so the scale of the increase cannot be assessed from the announcement.

India

Zoono says that momentum is starting to build in India in the agricultural sector, with repeat orders. The company describes the momentum as good and as starting to occur, and gives no order values, volumes or customer numbers for India.

Company background

Zoono describes itself as a global biotech company that develops, manufactures and distributes antimicrobial solutions that are scientifically validated, long-lasting and environmentally friendly. Its products include sprays, wipes and foams for skin care, surface sanitising and mould remediation, based on what it calls the zoono molecule, which it says bonds to surfaces and kills pathogens including bacteria, viruses, algae, fungi and mould. The company states its products carry numerous regulatory approvals and that its technology claims are supported by independent laboratory testing worldwide. The announcement was authorised by the Board and gives contact details for the Group Managing Director and Group CFO.

Reading the figures together

The NZ$110,000 unaudited July profit on NZ$625,000 of unaudited sales is a Margin of about 17.6%, although the announcement does not state what the profit measure includes, such as corporate costs or tax. The orders of circa NZ$700,000 received in July are higher than July sales, which suggests some order value was still to be delivered at month end, but the announcement does not confirm this. Because the update covers one month, it cannot show a trend across FY27.

What the update does not include

The release gives no cash balance, no full-year outlook, no breakdown of sales by product or region, and no values for the UK payment terms or India orders. It refers readers to the 7 July 2026 Quarterly Report (Appendix 4C) for the expectations on which the July orders were based. The headline of the announcement describes a good start to the year, and this article reports the underlying figures without adopting that characterisation.